Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations

Pharmazie

Volumn 67, Issue 7, 2012, Pages 639-644

  Zuo, Jinliang ^a,b   Xia, Dongya ^b   Jia, Lihui ^b   Guo, Tao ^b  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b SHENYANG NORTHERN HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GENOMIC DNA; CYP2C19 PROTEIN, HUMAN; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; CYTOCHROME P450 3A; DNA; DRUG; UNSPECIFIC MONOOXYGENASE;

ARTICLE; DNA EXTRACTION; ETHNIC GROUP; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPING TECHNIQUE; HAN CHINESE; HUI CHINESE; HUMAN; INCIDENCE; LEUKOCYTE; MONGOLIAN CHINESE; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; POPULATION GENETICS; UIGHUR CHINESE; ADULT; ASIAN; CHINA; FEMALE; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; MALE; METABOLISM; MONGOLIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MONGOLIA; PHARMACEUTICAL PREPARATIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84865622749     PISSN: 00317144     EISSN: None     Source Type: Journal    
DOI: 10.1691/ph.2012.1735     Document Type: Article

References (27)

1. Aithal GP, Day CP, Kesteven PJ, Daly AK (1999) Association of polymorphisms in the cytochromeP450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 3553: 717-719.
2. Alimu K, Amuti T, Niu ChY, et al (2007) Genetic polymorphism analysis of cytochrome CYP2C19 in Chinese Uigur and Han population. J XinJiang Medical University 30: 130-132.
3. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Iselius L, Sjöqvist F Reviriego J, Iselius L, Sjoqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylation of debrisoquine and S-mephenytoin. Clin Pharmacol Ther 51: 388-397.
4. Cai WM, Chen B, Liu YX, Chu X (1997) Dextromethorphan metabolic Phenotyping in a Chinese population. Acta Pharmacol Sin 18: 441-444.
5. Chu XM, CaoW, Min PQ, et al. (2003) Effect of CYP3A4 genetic polymorphism on cyclosporineAmetabolism in Chinese renal transplantrecipient. Chin J Clin Pharmocol 6: 421-425.
6. Daly AK (1995) Molecular basis of polymorphic drug metabolism. J Mol Med 73: 539-553.
7. Daly AK, Cholerton S, GregoryW, Idle JR (1993) Metabolic polymorphism. Pharmacol Ther 57: 129-160.
8. de Morais SMF,Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598.
9. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA (1995) The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 269: 15419-15422.
10. Ding HW, Dong ZhW, Jiang ZG, Ma X(2004) Cytochrome P450 2C19 Gene Polymorphism in 104 Chinese Zang Volunteers. Hereditas (Beijing) 26: 151-154.
11. Furuya H, Fernandez-Salguero P, Gregory W(1995) Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5: 389-392.
12. Gardiner SJ, Begg EJ (2006) Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 58: 521-590.
13. Ghodke Y, Joshi K, Arya Y, Radkar A, Chiplunkar A, Shintre P, Patwardhan B (2007) Genetic polymorphism of CYP2C19 in Maharashtrian population. Eur J Epidemiol 22: 907-915.
14. Goldstein JA, de Morais SMF (1994) Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285-99.
15. He ZhY, Pan W, Cui BQ, et al (2008) The study on the polymorph ism of T269C of CYP2C9 gene in Guangdong Population. J GuangDong College of Pharmacy 22: 312-322.
16. Hu YM, Qiao M, Xu JM (2007) Study on the CYP2C19 genetic polymorphism of Hall Chinese in Anhui province. Anhui Medical and Pharmaceutical 11: 717-719.
17. Ingelman-Sundberg M (2004) Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25: 193-200.
18. Ji Ling, Pan SX, Wu JM, et al (2002). Genetic polymorphisms of CYP2D6 in Chinese mainland. Chin Med.J 115: 1780-1784.
19. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A. (2005) Severalfold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 78: 540-550.
20. Meyer UA (1994) Pharmacogenetics The slow, the rapid, and the ultrarapid. Proc Natl Acad Sci USA 91: 1983-1984.
21. QiuXY, Jiao Z, Zhang M, Zhong LJ, Liang HQ,MaCL, Zhang L, ZhongMK (2008) Association of MDR1, CYP3A4*18B and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 64: 1069-1084.
22. Wang AN, Zhou HH (2005) Advance in search for cytochrome P450 3A4 gene mutation and phenotype. Chin J Clin Pharmacol 6: 459-461.
23. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM (1991) The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism - apanel study. Br J Clin Pharmacol 31: 689-692.
24. Wrighton SA, Vardonbradon M, Ring BJ (1996) The human drug metabolizing cytochromes P450. J Pharm Biopharm 24: 461-473.
25. Zhan GS, Zhou Q, Dong ZhW (2001) Cytochrome P450 2C19 Gene Polymorphism in Chinese Miao Population. Hereditas (Beijing) 23: 192-194.
26. Zhang S, Dong ZhW, Tang L, et al (2002) Cytochrome P450 2C19 gene olymorphism in four Chinese nationality populations. Chin J Med Genetl 9: 52-54.
27. ZhenY,Wu YJ,WuYM(2007) Sigle Nucleotide Polymorphism of CYP2D6 C188T and Susceptibillty to Lung Cancer. J Environ Occup Med 2: 167-169.